AstraZeneca’s stock underperforms EU pharma peers by 10% in 6 months

AstraZeneca’s recent trial failure for Wainua has eroded investor confidence in its pipeline premium. If the stock underperforms the EU pharma peer group by 10% or more by January 2027, it would signal broader skepticism about its long-term growth story.

price · Prediction Market

Implied probability (Yes)

72%

Closes

2027-01-11

More price markets

• Samsung Electronics market cap to exceed $1.2T by Q3 2026 — 78% Yes
• Cisco stock to rise above $65 by Q3 2026 — 72% Yes
• Private jet charter prices increase 20% in 2027 — 75% Yes
• Google Messages sees 30% user growth in 6 months post-launch — 70% Yes
• US AI chip ETF doubles in value by 2026-09-30 — 65% Yes
• X’s stock price rises 10% within 3 months of History tab launch — 55% Yes
• TSK enters top 5 Spanish engineering firms by market cap — 60% Yes
• Ford stock volatility exceeds 60% annualized within 6 months — 75% Yes

Browse all price markets →